NUC3373(Fosifloxuridine nafalbenamide)

  Cat. No.:  DC26034   Featured
Chemical Structure
1332837-31-6
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
NUC-3373 is a phosphoramidate-based prodrug of the monophosphate form of 5-fluoro-2'-deoxyuridine, the active metabolite of fluorouracil,an antimetabolite fluoropyrimidine analog of the pyrimidine nucleoside, with potential antineoplastic activity.
Cas No.: 1332837-31-6
Chemical Name: L-Alanine, N-(-2'-deoxy-2',2'-difluoro-p-1-naphthalenyl-5'-cytidylyl)-, phenylmethyl ester
Synonyms: 5-FU analog prodrug NUC-3373, nucleotide analog NUC-3373, phosphoramidate-FUDR-MP prodrug NUC-3373; NUC 3373; NUC3373
SMILES: C(OCC1=CC=CC=C1)(=O)[C@H](C)NP(C1=C2C(C=CC=C2)=CC=C1)(O)(=O)OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)[C@H0](F)(F)[C@@H]1O
Formula: C29H30F2N4O8P
M.Wt: 613.52
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: NUC-3373 is a phosphoramidate-based prodrug of the monophosphate form of 5-fluoro-2'-deoxyuridine, the active metabolite of fluorouracil,an antimetabolite fluoropyrimidine analog of the pyrimidine nucleoside, with potential antineoplastic activity.
In Vitro: A phosphoramidate-based prodrug of the monophosphate (MP) form of 5-fluoro-2'-deoxyuridine (FUdR; FUDR), the active metabolite of fluorouracil (5-FU), an antimetabolite fluoropyrimidine analog of the pyrimidine nucleoside, with potential antineoplastic activity. Upon administration of the nucleotide analog prodrug NUC-3373, NUC-3373 is readily taken up by tumor cells. In the tumor cell, the phosphoramidate moiety is removed and NUC-3373 is converted to its active form FUDR-MP. In turn, FUDR-MP binds to and inhibits thymidylate synthase (TS), resulting in the depletion of thymidine triphosphate (TTP) and thus DNA synthesis. With the phosphoramidate moiety attached to FUDR-MP, NUC-3373, compared to 5-FU, is more lipophilic and accumulates in cancer cells by passive diffusion and does not require a nucleoside transporter, thereby generating higher intracellular concentrations. In addition, compared to 5-FU, once inside the cell FUDR-MP does not need to be phosphorylated and is already in its active form. Unlike 5-FU, NUC-3373 does not get deactivated or converted into toxic metabolites by dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP), which leads to both a longer half-life and less toxicity.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
2018-0101
Cat. No. Product name Field of application
DC26034 NUC3373(Fosifloxuridine nafalbenamide) NUC-3373 is a phosphoramidate-based prodrug of the monophosphate form of 5-fluoro-2'-deoxyuridine, the active metabolite of fluorouracil,an antimetabolite fluoropyrimidine analog of the pyrimidine nucleoside, with potential antineoplastic activity.
X